Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02493530 · ClinicalTrials.gov registry record · Phase 1
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
A Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02493530: Completed Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Vanderbilt-Ingram Cancer Center.
NCT02493530 is a Phase 1 study of Myelofibrosis and Polycythemia Vera that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 60 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02493530, a Phase 1 study of Myelofibrosis and Polycythemia Vera, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.
Primary Outcome
All patients who have received at least one dose of TGR-1202 will be included in the safety population. All clinical safety data (vital signs, routine laboratory tests, and adverse events) will be tabulated and listed. The safety and tolerability of TGR-1202 and ruxolitinib will be evaluated by means of drug-related dose limiting toxicity, adverse event (AE) reports, physical examinations and laboratory safety evaluations.
Conditions Studied
Interventions
- DRUG ruxolitinib
- DRUG TGR-1202
Study Locations (5)
Arizona
- Mayo Clinic - Arizona - Phoenix
Colorado
- University of Colorado Cancer Center - Aurora
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- Mays Cancer Center at University of Texas Health San Antonio - San Antonio
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-07 |
| Est. Completion | 2024-05 |
| Phase | Phase 1 |
What the finished NCT02493530 record still lists
NCT02493530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which ruxolitinib is the first listed.
NCT02493530 lists 5 locations in 5 states (Arizona, Colorado, Tennessee).
Frequently Asked Questions
What is clinical trial NCT02493530 about?
NCT02493530 is a clinical study titled "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea". This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.
What is the current status of trial NCT02493530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-07. Estimated completion is 2024-05.
What conditions does trial NCT02493530 study?
This clinical trial studies the following conditions: Myelofibrosis, Polycythemia Vera.
What interventions are being tested in trial NCT02493530?
The interventions under investigation include: ruxolitinib (DRUG), TGR-1202 (DRUG).
Who is sponsoring clinical trial NCT02493530?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02493530 being conducted?
This trial has 5 study locations across Arizona, Colorado, Tennessee, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02493530's enrollment target sits among peer trials
60 28th of 61 higher than 34 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia